doi:10.3969/j.issn.1004-583X.2021.09.016

Abstract

CLC Number:

R541

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.09.016

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I9/843

Figures/Tables 1

References 64

[1]	Grisar JC, Haddad F, Gomari FA, et al. Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent[J]. Biomark Med, 2011, 5(6):731-744. doi: 10.2217/bmm.11.92 URL
[2]	Tiwari A, Mukherjee B, Dixit M. MicroRNA key to angiogenesis regulation: miRNA biology and therapy[J]. Curr Cancer Drug Targets, 2018, 18(3):266-277. doi: 10.2174/1568009617666170630142725 pmid: 28669338
[3]	Kanitz A, Imig J, Dziunycz PJ, et al. The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma[J]. PLoS One, 2012, 7(11):e49568. doi: 10.1371/journal.pone.0049568 URL
[4]	Liu D, Tao T, Xu B, et al. MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6)[J]. Biochem Biophys Res Commun, 2014, 445(1):151-156. doi: 10.1016/j.bbrc.2014.01.140 URL
[5]	Liu J, Yang J, Yu L, et al. miR-361-5p inhibits glioma migration and invasion by targeting SND1[J]. Onco Targets Ther, 2018, 11(1):5239-5252. doi: 10.2147/OTT URL
[6]	Hou XW, Sun X, Yu Y, et al. miR-361-5p suppresses lung cancer cell lines progression by targeting FOXM1[J]. Neoplasma, 2017, 64(4):526-534. doi: 10.4149/neo_2017_406 pmid: 28485158
[7]	Liu B, Lu B, Wang X, et al. MiR-361-5p inhibits cell proliferation and induces cell apoptosis in retinoblastoma by negatively regulating CLDN8[J]. Childs Nerv Syst, 2019, 35(8):1303-1311. doi: 10.1007/s00381-019-04199-9 URL
[8]	Ma F, Zhang L, Ma L, et al. MiR-361-5p inhibits glycolytic metabolism, proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1[J]. J Exp Clin Cancer Res, 2017, 36(1):158. doi: 10.1186/s13046-017-0630-1 URL
[9]	Gao F, Feng J, Yao H, et al. LncRNA SBF2-AS1 promotes the progression of cervical cancer by regulating miR-361-5p/FOXM1 axis[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1):776-782. doi: 10.1080/21691401.2019.1577883 URL
[10]	Wang K, Liu F, Zhou LY, et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489[J]. Circ Res, 2014, 114(9):1377-1388. doi: 10.1161/CIRCRESAHA.114.302476 pmid: 24557880
[11]	Dorn GW 2nd, Matkovich SJ. Menage a Trois: Intimate relationship among a microRNA, long noncoding RNA, and mRNA[J]. Circ Res, 2014, 114(9):1362-1365. doi: 10.1161/CIRCRESAHA.114.303786 URL
[12]	Wang J, Uryga AK, Reinhold J, et al. Vascular smooth muscle cell senescence promotes atherosclerosis and features of plaque vulnerability[J]. Circulation, 2015, 132(20):1909-1919. doi: 10.1161/CIRCULATIONAHA.115.016457 URL
[13]	Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis[J]. Cell, 2011, 145(3):341-355. doi: 10.1016/j.cell.2011.04.005 URL
[14]	Zhang X, Ye Q, Gong D, et al. Apelin-13 inhibits lipoprotein lipase expression via the APJ/PKCα/miR-361-5p signaling pathway in THP-1 macrophage-derived foam cells[J]. Acta Biochim Biophys Sin (Shanghai), 2017, 49(6):530-540. doi: 10.1093/abbs/gmx038 URL
[15]	Ricart JD, Cejudo MP, Peinado OJ, et al. Changes in lipoprotein lipase modulate tissue energy supply during stress[J]. J Appl Physiol(1985), 2005, 99(4):1343-1351.
[16]	Zhang Z, Liu X, Xu H, et al. Obesity-induced upregulation of miR-361-5p promotes hepatosteatosis through targeting Sirt1[J]. Metabolism, 2018, 88:31-39. doi: 10.1016/j.metabol.2018.08.007 URL
[17]	Huang K, Yu X, Yu Y, et al. Long noncoding RNA MALAT1 promotes high glucose-induced inflammation and apoptosis of vascular endothelial cells by regulating miR-361-3p/SOCS3 axis[J]. Int J Clin Exp Pathol, 2020, 13(5):1243-1252.
[18]	Giardina S, Hernández AP, Díaz L, et al. Changes in circulating miRNAs in healthy overweight and obese subjects: Effect of diet composition and weight loss[J]. Clin Nutr, 2019, 38(1):438-443. doi: S0261-5614(17)31412-7 pmid: 29233588
[19]	Wang P, Xu TY, Guan YF, et al. Vascular smooth muscle cell apoptosis is an early trigger for hypothyroid atherosclerosis[J]. Cardiovasc Res, 2014, 102(3):448-459. doi: 10.1093/cvr/cvu056 pmid: 24604622
[20]	Willis AI, Pierre PD, Sumpio BE, et al. Vascular smooth muscle cell migration: Current research and clinical implications[J]. Vasc Endovascular Surg, 2014, 38(1):11-23. doi: 10.1177/153857440403800102 URL
[21]	Wang M, Li C, Zhang Y, et al. LncRNA MEG3-derived miR-361-5p regulate vascular smooth muscle cells proliferation and apoptosis by targeting ABCA1[J]. Am J Transl Res, 2019, 11(6):3600-3609.
[22]	Castiglioni S, Monti M, Arnaboldi L, et al. ABCA1 and HDL are required to modulate smooth muscle cells phenotypic switch after cholesterol loading[J]. Atherosclerosis, 2017, 266(1):8-15. doi: 10.1016/j.atherosclerosis.2017.09.012 URL
[23]	Bochem AE, Valk FM, Tolani S, Increased systemic and plaque inflammation in ABCA1 mutation carriers with attenuation by statins[J]. Arterioscler Thromb Vasc Biol, 2015, 35(7):1663-1669. doi: 10.1161/ATVBAHA.114.304959 URL
[24]	Li C, Guo R, Lou J, et al. The transcription levels of ABCA1, ABCG1 and SR-BI are negatively associated with plasma CRP in Chinese populations with various risk factors for atherosclerosis[J]. Inflammation, 2012, 35(5):1641-1648. doi: 10.1007/s10753-012-9479-9 URL
[25]	Mulas MF, Maxia A, Dessì S, et al. Cholesterol esterification as a mediator of proliferation of vascular smooth muscle cells and peripheral blood mononuclear cells during atherogenesis[J]. J Vasc Res, 2014, 51(1):14-26. doi: 10.1159/000355218 URL
[26]	He C, Chen Y, Liu C, et al. Mitofusin 2 decreases intracellular cholesterol of oxidized LDL-induced foam cells from rat vascular smooth muscle cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2013, 33(2):212-218. doi: 10.1007/s11596-013-1099-6 URL
[27]	Zhang X, Shao R, Gao W, et al. Inhibition of miR-361-5p suppressed pulmonary artery smooth muscle cell survival and migration by targeting ABCA1 and inhibiting the JAK2/STAT3 pathway[J]. Exp Cell Res, 2018, 363(2):255-261. doi: 10.1016/j.yexcr.2018.01.015 URL
[28]	White HD, Chew DP. Acute myocardial infarction[J]. Lancet, 2018, 372(9638):570-584. doi: 10.1016/S0140-6736(08)61237-4 URL
[29]	Wang F, Long G, Zhao C, et al. Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction[J]. PLoS One, 2014, 9(9):e105734. doi: 10.1371/journal.pone.0105734 URL
[30]	王明辉. LncRNA MEG3及miRNA-361-5p在冠状动脉粥样硬化中的作用及机制[D]. 天津:天津医科大学, 2019:38-58.
[31]	Su J, Fang M, Tian B, et al. Atorvastatin protects cardiac progenitor cells from hypoxia-induced cell growth inhibition via MEG3/miR-22/HMGB1 pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50(12):1257-1265. doi: 10.1093/abbs/gmy133 URL
[32]	Li X, Zhao J, Geng J, et al. Long non-coding RNA MEG3 knockdown attenuates endoplasmic reticulum stress-mediated apoptosis by targeting p53 following myocardial infarction[J]. J Cell Mol Med, 2019, 23(12):8369-8380. doi: 10.1111/jcmm.v23.12 URL
[33]	Marzetti E, Calvani R, Cesari M, et al. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials[J]. Int J Biochem Cell Biol, 2013, 45(10):2288-2301. doi: 10.1016/j.biocel.2013.06.024 URL
[34]	Su B, Wang X, Zheng L, et al. Abnormal mitochondrial dynamics and neurodegenerative diseases[J]. Biochim Biophys Acta, 2010, 1802(1):135-142.
[35]	Wang W, Li L, Lin WL, et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons[J]. Hum Mol Genet, 2013, 22(23):4706-4719. doi: 10.1093/hmg/ddt319 URL
[36]	Wang K, Liu CY, Zhang XJ, et al. miR-361-regulated prohibitin inhibits mitochondrial fission and apoptosis and protects heart from ischemia injury[J]. Cell Death Differ, 2015, 22(6):1058-1068. doi: 10.1038/cdd.2014.200 pmid: 25501599
[37]	Wang K, Sun T, Li N, et al. MDRL lncRNA regulates the processing of miR-484 primary transcript by targeting miR-361[J]. PLoS Genet, 2014, 10(7):e1004467. doi: 10.1371/journal.pgen.1004467 URL
[38]	Wang HW, Lo HH, Chiu YL, et al. Dysregulated miR-361-5p/VEGF axis in the plasma and endothelial progenitor cells of patients with coronary artery disease[J]. PLoS One, 2014, 9(5):e98070. doi: 10.1371/journal.pone.0098070 URL
[39]	Xie Y, Yao FL, Li X. MicroRNA-361 regulates apoptosis of cardiomyocytes after ischemic-reperfusion injury[J]. Eur Rev Med Pharmacol Sci, 2019, 23(12):5413-5421.
[40]	Zhong Z, Zhong W, Zhang Q, et al. Circulating microRNA expression profiling and bioinformatics analysis of patients with coronary artery disease by RNA sequencing[J]. J Clin Lab Anal, 2020, 34(1):e23020.
[41]	Su M, Niu Y, Dang Q, et al. Circulating microRNA profiles based on direct S-Poly(T)Plus assay for detection of coronary heart disease[J]. J Cell Mol Med, 2020, 24(11):5984-5997. doi: 10.1111/jcmm.v24.11 URL
[42]	Peshkova IO, Schaefer G, Koltsova EK. Atherosclerosis and aortic aneurysm-is inflammation a common denominator?[J]. FEBS J, 2016, 283(9):1636-1652. doi: 10.1111/febs.13634 pmid: 26700480
[43]	Yu X, Liu X, Wang R, et al. Long non-coding RNA NEAT1 promotes the progression of hemangioma via the miR-361-5p/VEGFA pathway[J]. Biochem Biophys Res Commun, 2019, 512(4):825-831. doi: 10.1016/j.bbrc.2019.03.084 URL
[44]	Airhart N, Brownstein BH, Cobb JP, et al. Smooth muscle cells from abdominal aortic aneurysms are unique and can independently and synergistically degrade insoluble elastin[J]. J Vasc Surg, 2014, 60(4): 1033-1041; discussion 1041-1042. doi: 10.1016/j.jvs.2013.07.097 pmid: 24080131
[45]	Yin RR, Hao D, Chen P. Expression and correlation of MMP-9, VEGF, and p16 in infantile hemangioma[J]. Eur Rev Med Pharmacol Sci, 2018, 22(15):4806-4811.
[46]	Donaldson JW, McKeever TM, Hall IP, et al. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: A population-based study[J]. Thorax, 2014, 69(2):161-167. doi: 10.1136/thoraxjnl-2013-203720 pmid: 24188926
[47]	Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels[J]. Arterioscler Thromb Vasc Biol, 2004, 24(3):435-44. pmid: 14604834
[48]	Bach Leon A. Endothelial cells and the IGF system[J]. J Mol Endocrinol, 2015, 54(1):R1-13. doi: 10.1530/JME-14-0215 URL
[49]	Friedrich CC, Lin Y, Krannich A, et al. Enhancing engineered vascular networks in vitro and in vivo: The effects of IGF1 on vascular development and durability[J]. Cell Prolif, 2018, 51(1): undefined.
[50]	Zawistowski JS, Stalheim L, Uhlik MT, et al. CCM1 and CCM2 protein interactions in cell signaling: Implications for cerebral cavernous malformations pathogenesis[J]. Hum Mol Genet, 2005, 14(17):2521-2531. pmid: 16037064
[51]	Kar S, Bali Kiran K, Baisantry A, et al. Genome-wide sequencing reveals micrornas downregulated in cerebral cavernous malformations[J]. J Mol Neurosci, 2017, 61(2):178-188. doi: 10.1007/s12031-017-0880-6 URL
[52]	Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension[J]. Rev Esp Cardiol (Engl Ed), 2016, 69(2):177.
[53]	Zhang Y, Chen Y, Chen G, et al. Upregulation of miR-361-3p suppresses serotonin-induced proliferation in human pulmonary artery smooth muscle cells by targeting SERT[J]. Cell Mol Biol Lett, 2020, 25:45. doi: 10.1186/s11658-020-00237-6 pmid: 33061998
[54]	Dal Monte M, Landi D, Martini D, et al. Antiangiogenic role of miR-361 in human umbilical vein endothelial cells: functional interaction with the peptide somatostatin[J]. Naunyn Schmiedebergs Arch Pharmacol, 2013, 386(1):15-27. doi: 10.1007/s00210-012-0808-1 URL
[55]	Wei C, Henderson H, Spradley C, et al. Circulating miRNAs as potential marker for pulmonary hypertension[J]. PLoS One, 2013, 8(5):e64396. doi: 10.1371/journal.pone.0064396 URL
[56]	Shiraev TP, Omari A, Rushworth RL. Trends in pulmonary embolism morbidity and mortality in Australia[J]. Thromb Res, 2013, 132(1):19-25. doi: 10.1016/j.thromres.2013.04.032 URL
[57]	Wang W, Zhu X, Du X, et al. MiR-150 promotes angiogensis and proliferation of endothelial progenitor cells in deep venous thrombosis by targeting SRCIN1[J]. Microvasc Res, 2019, 123(1):35-41. doi: 10.1016/j.mvr.2018.10.003 URL
[58]	Ozkok A, Yildiz A. Endothelial Progenitor Cells and Kidney Diseases[J]. Kidney Blood Press Res, 2018, 43(3):701-718. doi: 10.1159/000489745 URL
[59]	Yang X, Song Y, Sun Y, et al. Down-regulation of miR-361-5p promotes the viability, migration and tube formation of endothelial progenitor cells via targeting FGF1[J]. Biosci Rep, 2020, 40(10):BSR20200557.
[60]	Wang X, Sundquist K, Svensson PJ, et al. Association of recurrent venous thromboembolism and circulating microRNAs[J]. Clin Epigenetics, 2019, 11(1):28. doi: 10.1186/s13148-019-0627-z URL
[61]	牟建军, 任珂宇. 盐敏感性高血压的诊断和机制[J]. 诊断学理论与实践, 2012, 11(6):543-546.
[62]	Kelly TN, He J. Genomic epidemiology of blood pressure salt sensitivity[J]. J Hypertens, 30(5):861-873. doi: 10.1097/HJH.0b013e3283524949 URL
[63]	Qi H, Liu Z, Liu B, et al. micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension[J]. Medicine (Baltimore), 2017, 96(17):e6417. doi: 10.1097/MD.0000000000006417 URL
[64]	Kanehisa M, Goto S, Sato Y, et al. KEGG for integration and interpretation of large-scale molecular data sets[J]. Nucleic Acids Res, 2012, 40(1):D109-114. doi: 10.1093/nar/gkr988 URL

疾病类型	相关通路	ceRNA	靶基因	生物学功能
AS	APJ/PKCa JAK2/STAT3	MALAT1 MEG3	LPL Sirt1 SOCS3 SH2B1 ABCA1	参与糖、脂质代谢、细胞增殖转移,抑制炎症因子
AMI	未知	MEG3	PHB1 VEGF BCL2/BAX p53	参与血管生成、细胞增殖转移、抑制凋亡,影响线粒体功能
HA HHT CCM	TGFβ/BMP	NEAT1	VEGFA IGF1 RAC1 CCM2	参与血管生成、细胞增殖转移、细胞外基质降解
PAH	JAK/STAT3	未知	SERT VEGF ABCA1	参与血管重塑、脂质代谢、细胞增殖转移
VTE	TGFβ1/2	未知	FGF1	参与血管生成、细胞增殖转移
SSH	未知	OTX1-7:1	PRKCA	参与钙信号、血管平滑肌收缩、钠重吸收,调控钠离子转运体

疾病类型	相关通路	ceRNA	靶基因	生物学功能
AS	APJ/PKCa JAK2/STAT3	MALAT1 MEG3	LPL Sirt1 SOCS3 SH2B1 ABCA1	参与糖、脂质代谢、细胞增殖转移,抑制炎症因子
AMI	未知	MEG3	PHB1 VEGF BCL2/BAX p53	参与血管生成、细胞增殖转移、抑制凋亡,影响线粒体功能
HA HHT CCM	TGFβ/BMP	NEAT1	VEGFA IGF1 RAC1 CCM2	参与血管生成、细胞增殖转移、细胞外基质降解
PAH	JAK/STAT3	未知	SERT VEGF ABCA1	参与血管重塑、脂质代谢、细胞增殖转移
VTE	TGFβ1/2	未知	FGF1	参与血管生成、细胞增殖转移
SSH	未知	OTX1-7:1	PRKCA	参与钙信号、血管平滑肌收缩、钠重吸收,调控钠离子转运体

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 64

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(2): 188-192.
[2]	Huang Yuling, Zhang Xinyue, Rong Pingping, Yang Wenqi, Cao Xinying, Xing Cainai, Wang Zhijun, Liu Ning. Correlation analysis of Non-HDL-C/HDL-C and NHR with the severity of coronary artery disease [J]. Clinical Focus, 2024, 39(2): 115-120.
[3]	Wang Yihan, Qin Xuyan, Han Xuanze, Wang Yingjie, Gao Feifei, Chen Chunhong, Zhang Lingnan, Zhang Fang. Efficacy and safety of rivaroxaban therapy in elderly patients with non-valvular atrial fibrillation who had a HASBLED score≥3 [J]. Clinical Focus, 2024, 39(2): 121-124.
[4]	. [J]. Clinical Focus, 2024, 39(2): 168-171.
[5]	. [J]. Clinical Focus, 2024, 39(1): 75-79.
[6]	. [J]. Clinical Focus, 2024, 39(1): 80-83.
[7]	Li Lisha, Shen Xianghui, Liu Yanhui, Ren Yanbin. Aortic root anatomy and atrial septal mobility analyzed by transesophageal echocardiography [J]. Clinical Focus, 2023, 38(11): 1012-1015.
[8]	Wang Jiaqi, Xie Yuetao, Gao Man, Song Xuelian, Zhang Feifei, Dang Yi, Qi Xiaoyong. Treatment of variant angina pectoris guided by the optical coherence tomography: A case report and literature review [J]. Clinical Focus, 2023, 38(10): 917-921.
[9]	Yang Changlin, Cao Shufeng, Qiao Lian, Zhao Huimin. Type I Kounis syndrome caused by drug allergy: A case report [J]. Clinical Focus, 2023, 38(10): 922-925.
[10]	Duan Fang, Cui Wei. Application principles of vasodilators in the treatment of acute heart failure [J]. Clinical Focus, 2023, 38(9): 773-778.
[11]	Wei Yuhan, Zhao Yanan, Zhang Guibin, Wu Yuqing, Dong Bohua, Hu Jiayuan, Yang Wenqi. Correlation analysis of monocyte-to-high density lipoprotein cholesterol ratio, red cell distribution width, and uric acid with the severity of coronary artery disease in patients with coronary heart disease [J]. Clinical Focus, 2023, 38(9): 796-801.
[12]	Li Hua, Chen Jianjun, Wei Jitao, Zhang Qi. Correlation between serum cystatin C level and nonobstructive coronary artery disease [J]. Clinical Focus, 2023, 38(9): 802-805.
[13]	. [J]. Clinical Focus, 2023, 38(9): 832-837.
[14]	. [J]. Clinical Focus, 2023, 38(9): 838-844.
[15]	Liu Duo, Li Yanling, Guo Zhaoxia, Li Jianfeng, Zhang Huijuan, Xie Ping. Anomalous left coronary artery from the pulmonary artery: A case report and literature review [J]. Clinical Focus, 2023, 38(7): 618-622.